The Impact of Qualia Gluthathione+ on Blood Glutathione Levels

What Was Tested

This registered not phased trial tested Glutathione.

Each participant will take two or three capsules of their assigned product once daily in the morning, with or without food, over a 20-day period.

It had three arms (groups): one (active comparator), one (active comparator) and Placebo (placebo comparator).

Rice flour placebo.

The registry classes the interventions as dietary supplement.

More on the Plan

Note on allocation (added September 2026): Participants were assigned to study arms by systematic allocation rather than by random allocation.

Earlier versions of this record described the design as randomized.

The Allocation field and the design descriptions were corrected to Non-Randomized to reflect the method actually used.

No other aspect of the study design, conduct, or analysis changed.

Who Took Part

The registry lists 56 actual participants took part.

It was open to people of any sex aged from 45 years up to 75 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Provide voluntary, written, informed consent to participate in the study. Agree to provide a valid cell phone number and are willing to receive communications through text. Can read and write English. Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly. Healthy male and female participants aged 45-75 years.

The full record lists 8 inclusion and 9 exclusion criteria; among the exclusions: women who are pregnant, breastfeeding, or planning to become pregnant during the trial; known food intolerances/allergy to any ingredients in the product; having any of the following conditions: psychiatric conditions, neurologic disorders, endocrine disorders, cancer.

How the Study Was Run

The set-up was non-randomized, parallel-group and quadruple-blind.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Neither the participants nor the staff measuring them knew who was on Glutathione, so expectations could not easily colour the readings.

Those kept unaware of assignments: participant, care provider, investigator and outcomes assessor.

It started in 2025-11-30 with completion listed for 2025-12-22.

It ran at 1 site in United States.

Its stated primary purpose is other.

What Was Measured

The main thing measured (primary outcome): Total Glutathione levels from baseline to Day 20 (time frame: 0-20 days).

It also tracked 6 secondary outcomes, for example between-group differences in blood Total Glutathione levels, within-group differences in the change in blood Glutathione levels, Safety and Tolerability survey, PROMIS Global Health-10, PROMIS Short Form v1.0 - Fatigue 10a and PROMIS Cognitive Function - Short Form 8a.

What This Means in Plain Language

Put simply, this is a not phased, non-randomized trial of Glutathione in 56 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Glutathione compound page, all human trials.